Safety

Atacand (Candesartan Cilexetil) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

February 2016

Summary View

WARNINGS AND PRECAUTIONS

Hyperkalemia
  • Concomitant use of ATACAND with drugs that may increase potassium levels may increase the risk of hyperkalemia [see Drug Interactions (7)]. Monitor serum potassium periodically

DRUG INTERACTIONS

Agents Increasing Serum Potassium Other drugs that affect serum potassium
  • Coadministration of ATACAND with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Lithium
  • Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium

 

February 2015

Summary View

DRUG INTERACTIONS

Lithium
  • Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including Atacand.  

April 2013

Summary View

CONTRAINDICATIONS

  • Atacand is contraindicated in patients who are hypersensitive to candesartan. Do not administer Aliskiren with Atacand in patients with diabetes.

WARNINGS AND PRECAUTIONS

Hypotension
  • Atacand can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting…
  • In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, hypotension was reported in 22.6% of patients treated with Atacand versus 13.8% treated with placebo.
Impaired Renal Function
  • In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, the incidence of abnormal renal function (e.g.,creatinine increase) was 15% in patients treated with Atacand versus 9% in patients treated with placebo
Hyperkalemia
  • In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with Atacand versus 3.5% in patients treated with placebo. 

ADVERSE REACTIONS

Postmarketing Experience
  • Immunologic: Angioedema

USE IN SPECIFIC POPULATIONS

Patient Information - Who should not take Atacand?
  • are diabetic and taking Aliskiren

 

Page Last Updated: 03/14/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English